GRCE

$2.07-$0.03 (-1.43%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$44.2M

21M shares

52-week range

$1.79 – $5.18

8% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-1.14

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$5M	+1011.1%	$-0.66	$-0.80–$-0.51	—	1
2028	$6M	+13.9%	$-0.56	$-0.62–$-0.49	—	2
2029	$100M	+1656.0%	$1.60	$1.25–$1.95	1.3×	1
2030	$140M	+40.0%	$2.40	$1.88–$2.92	0.9×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-0.13	$-0.91	-603.8%
2026-06-18	$-0.24	$-0.07	+70.8%
2026-02-12	$-0.09	$-0.14	-55.6%
2025-11-13	$-0.12	$-0.15	-25.0%
2025-08-12	$-0.22	$-0.21	+4.5%
2025-06-23	$-0.20	$0.06	+132.3%
2025-02-13	$-0.24	$-0.26	-8.3%
2024-11-13	$-0.33

DCF fair valuemodel estimate

Intrinsic value

$0.71

Price

$2.07

Implied downside

-66%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GRCEGrace Therapeutics, Inc.	$2.07	-1.43%	$34M	—
ABVCABVC BioPharma, Inc.	$0.96	-0.07%	$25M	—
ATNMActinium Pharmaceuticals, Inc.	$0.96	+17.39%	$30M	—
CALCCalciMedica, Inc.	$0.66	+6.03%	$10M	—
LTRNLantern Pharma Inc.	$2.63	-1.13%

Grace Therapeutics, Inc. Common Stock

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.

www.gracetx.com

Employees: 5
IPO / List date: Apr 26, 2011
HQ: PRINCETON, NJ

Held by traders on TradeandTell

No one on the platform currently holds GRCE.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	243,910	$1.1M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded GRCE yet.

$GRCE chatter on StockTwits

BB_88_@BB_88_13h
$GRCE need to launch it soon
View on StockTwits ↗
jorge .miguel@focafoca9921h
$GRCE announced its Q2 2026 results for the quarter ended June 30, 2026. https://www.rapidticker.com/news/grce-sec-filing-2976bd
View on StockTwits ↗
alex pitti@alexpitti3d
$GRCE very likely has had health economic talks based on its presentation. Sorry i was wrong
View on StockTwits ↗
The Stock Market Conqueror@Market_Luther_Kang3d
$GRCE Anyone know if the company has started payer/insurance conversations for GTx-104 yet? Given aSAH skews younger (~50% under 60 per their own deck), Medicare NTAP seems less relevant than commercial payer coverage, but I can't find any market access hire or payer engagement disclosure anywhere. Missing something or is this genuinely not addressed yet?
View on StockTwits ↗
alex pitti@alexpitti3d
$GRCE has 10x potential. 3x times $200 million in sales
View on StockTwits ↗
alex pitti@alexpitti4d
$GRCE my friend sold his entire position
View on StockTwits ↗
alex pitti@alexpitti5d
no clue why anyone would be short $GRCE company is in no man's land and will probably do nothing until they get close to submitting in 6-9 months, but i don't see any downside
View on StockTwits ↗
Ct Sreenath@Happiness10centsAug 7
$GRCE Timeline from the recent announcement (i) the U.S.-based facility, which would require completion of a full chemistry, manufacturing, and controls (“CMC”) package supported by 12 months of stability data following the technology transfer; or (ii) the Company’s current contract manufacturer, if it successfully remediates its FDA compliance issues and is able to support the NDA sooner. The Company is also advancing efforts to address the remaining CMC and non-clinical items identified in FDA’s Complete Response Letter (“CRL”) to the NDA, though the Company expects that manufacturing readiness, rather than these items, will be the key driver of NDA resubmission timing. @CharlieeMungerTWITS The language in point 2 suggests.. manufacturing readiness determines the timeline. The first cdmo (foreign country) requires a FDA reinspection (6-12 months) before resubmission . The second cdmo in the US needs to do cmc + 12 months stability test. PROBABLY 18 - 24 MONTHS TO APPROVAL
View on StockTwits ↗
jorge .miguel@focafoca99Aug 6
$GRCE conducted a $10 million private placement, selling 4.76 million shares at $2.10 each. https://www.rapidticker.com/news/grce-sec-filing-255897
View on StockTwits ↗
BB_88_@BB_88_BullishAug 6
$GRCE private placement - good stuff last time did one of these we were at 1.8 then rode to 5 - she still good long term hold now
View on StockTwits ↗
alex pitti@alexpittiAug 6
$GRCE i wonder if grace issued shares because they know they won't be submitting for re approval this year. because if they are going to resubmit in 3-5 months, just hold off on the private placement
View on StockTwits ↗
ccledez@ccledezBullishAug 5
$UNCY not that it really matters But Gemini states the most likely to report positive news are now (just the order) Uncy 1st $CING 2nd $GRCE 3rd 😂
View on StockTwits ↗
MZ2X@MZ2XBullishAug 5
$GRCE looking for re entry
View on StockTwits ↗
The Stock Market Conqueror@Market_Luther_KangAug 5
$GRCE there it is
View on StockTwits ↗
Munger Charliee@CharlieeMungerTWITSBullishAug 5
$GRCE MORE POWDER YOOOOO
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.